Compare STEX & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEX | SERA |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.8M | 107.3M |
| IPO Year | N/A | 2021 |
| Metric | STEX | SERA |
|---|---|---|
| Price | $2.05 | $2.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 23.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.66 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $77,000.00 |
| Revenue This Year | N/A | $25.84 |
| Revenue Next Year | N/A | $715.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.04 | $1.37 |
| 52 Week High | $7.44 | $4.35 |
| Indicator | STEX | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 32.43 | 27.11 |
| Support Level | N/A | $1.37 |
| Resistance Level | $3.68 | $3.45 |
| Average True Range (ATR) | 0.26 | 0.21 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 4.83 | 7.14 |
Streamex Corp is a vertically integrated technology and infrastructure company. It is focused on the tokenization and digitalization of real-world assets. The group provides institutional-grade solutions that bring traditional commodities and assets on-chain through secure, regulated, and yield-bearing financial instruments. It is committed to delivering transparent, scalable, and compliant digital asset solutions that bridge the gap between traditional finance and blockchain-enabled markets.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.